This 700-page report is an all-inclusive strategic and reference therapeutic manual. Covering over 200 therapeutic categories, the report provides an extensive analysis of current therapies and prospective products.
The data in Scrip's Complete Guide to Therapeutic Trends has been collated from PJB's extensive leading R&D database � Pharmaprojects � and has been indexed and cross-referenced by disease, to enable you to access the information you need quickly and easily. This material is further supplemented with thorough independent research to provide you with informed commentary and analysis of all the R&D areas receiving significant attention.
The information in this thorough guide will enable you to answer major questions, such as:
This report will equip you to evaluate therapeutic areas of significant growth, and assess new opportunities for the development of your own therapeutic product.
Published: November 2000
Ref: BS1080E
Pages: 700
Price: £695/$1,460/¥167,000
CONTENTS
LIST OF TABLES
LIST OF FIGURES
METHODOLOGY
INTRODUCTION AN OVERVIEW OF THE PHARMACEUTICAL MARKET
ABBREVIATIONS
(A) ALIMENTARY/METABOLIC PRODUCTS
STOMATOLOGICAL (A1A)
ANTACID/ANTIFLATULENT (A2A)
ANTIULCER, PROSTAGLANDIN (A2B2)
ANTIULCER (A2B9)
ANTISPASMODIC (A3)
ANTIEMETIC (A4A)
GASTROPROKINETIC (A4B)
HEPATOPROTECTIVE (A5B)
GALLSTONE THERAPY (A5D)
LAXATIVE (A6)
ANTIDIARRHOEAL (A7)
ANORETIC/ANTIOBESITY (A8A3)
DIGESTIVE (A9)
ANTIDIABETIC (A10B)
SYMPTOMATIC ANTIDIABETIC (A10C)
NUTRITIONAL SUPPLEMENT (A11A)
ANABOLIC (A14)
APPETITE STIMULANT (A15)
ALIMENTARY/METABOLIC (A16)
(B) BLOOD AND CLOTTING PRODUCTS
ANTICOAGULANT (B1A)
FIBRINOLYTIC (B1B1)
ANTITHROMBOTIC (B1B9)
ANTIFIBRINOLYTIC (B2A)
HAEMOSTATIC (B2B)
ANTISICKLING (B3C1)
ANTIANAEMIC (B3C9)
PLASMA SUBSTITUTE (B5A1)
BLOOD FRACTION (B5A2)
SEPTIC SHOCK TREATMENT (B6A)
(C) CARDIOVASCULAR PRODUCTS
HAEMATOLOGICAL (B7Z)
ANTIARRHYTHMIC (C1B)
CARDIOSTIMULANT (C1C1)
VASODILATOR, CORONARY (C1D1)
ANTIANGINAL (C1D3)
ANTIHYPERTENSIVE, ADRENERGIC (C2B1)
ANTIHYPERTENSIVE, RENIN SYSTEM (C2B2)
ANTIHYPERTENSIVE, DIURETIC (C2B6)
ANTIHYPERTENSIVE, OTHER (C2B9)
VASODILATOR, PERIPHERAL (C4A)
VASODILATOR, RENAL (C4B)
VASOPROTECTIVE, TOPICAL (C5A)
VASOPROTECTIVE, SYSTEMIC (C5C)
HYPERTENSIVE (C6C)
CARDIOVASCULAR (C9Z)
(D) DERMATOLOGICAL PRODUCTS
VULNERARY (D3A)
ANTIPRURITIC/INFLAMMATORY, ALLERGIC (D4A)
ANTIPRURITIC/INFLAMMATORY, NON-ALLERGIC (D4B)
ANTIPSORIASIS (D5A)
ANTIACNE (D10A)
DERMATOLOGICAL (D11Z)
(G) GENITOURINARY PRODUCTS
FERTILITY ENHANCER (G1C)
LABOUR INDUCER (G2A)
LABOUR INHIBITOR (G2B)
MENSTRUATION DISORDERS (G3A)
MENOPAUSAL DISORDERS (G3B)
FEMALE CONTRACEPTIVE (G3C)
ABORTIFACIENT (G3D)
UROLOGICAL (G4Z)
PROSTATE DISORDERS (G5A)
MALE SEXUAL DYSFUNCTION (G5B)
MALE CONTRACEPTIVE (G5C)
REPRODUCTIVE/GONADAL, GENERAL (G6Z)
(H) HORMONAL PRODUCTS
THYROID HORMONE (H3A)
ANTITHYROID (H3B)
PROSTAGLANDIN (H4B)
RELEASING HORMONES (H4C)
ANTIPROLACTIN (H4D2)
INSULIN (H4E1)
GLUCAGON (H4E2)
GROWTH HORMONE (H4F1)
SOMATOSTATIN (H4F2)
HORMONE (H4Z)
(I) IMMUNOLOGICAL PRODUCTS
IMMUNOSTIMULANT, ANTI-AIDS (I1A)
IMMUNOSTIMULANT, OTHER (I1Z)
CYTOKINE (I2)
IMMUNOGLOBULIN, NON-MAB (I4A2)
IMMUNOSUPPRESSANT (I5)
IMMUNOLOGICAL (I6Z)
(J) ANTI-INFECTIVE PRODUCTS
TETRACYCLINE (J1A)
PENICILLIN, ORAL (J1C1)
PENICILLIN, INJECTABLE (J1C2)
CEPHALOSPORIN, ORAL (J1D1)
CEPHALOSPORIN, INJECTABLE (J1D2)
TRIMETHOPRIM AND ANALOGUES (J1E)
MACROLIDE ANTIBIOTIC (J1F)
AMINOGLYCOSIDE ANTIBIOTIC (J1L)
PEPTIDE ANTIBIOTIC (J1M)
BETA-LACTAM ANTIBIOTIC (J1N)
ANTIBIOTIC, OTHER (J1Z)
ANTIFUNGAL (J2A)
QUINOLONE ANTIBACTERIAL (J3C)
ANTIBACTERIAL, OTHER (J3Z)
ANTIMYCOBACTERIAL (J4A)
ANTIVIRAL, ANTI-HIV (J5A)
ANTIVIRAL, INTERFERON (J5B)
ANTIVIRAL, OTHER (J5Z)
PROPHYLACTIC VACCINE (J7A1)
THERAPEUTIC VACCINE (J7A2)
IMMUNOMODULATOR, ANTI-INFECTIVE (J7B)
ANTI-INFECTIVE, OTHER (J8Z)
(K) ANTICANCER PRODUCTS
ANTICANCER, ANTIBIOTIC (K1A)
ANTICANCER, ALKYLATING (K1B)
ANTICANCER, ANTIMETABOLITE (K1C)
ANTICANCER, HORMONAL (K2)
ANTICANCER, IMMUNOLOGICAL (K3)
ANTICANCER, INTERFERON (K4)
RADIO/CHEMOSENSITIZER (K5A)
RADIO/CHEMOPROTECTIVE (K5B)
ANTICANCER, OTHER (K6Z)
(M) MUSCULOSKELETAL PRODUCTS
ANTI-INFLAMMATORY (M1A1)
ANTI-INFLAMMATORY, TOPICAL (M1A2)
ANTIARTHRITIC, IMMUNOLOGICAL (M2C)
ANTIARTHRITIC, OTHER (M2Z)
MUSCLE RELAXANT (M3)
ANTIGOUT (M4A)
OSTEOPOROSIS TREATMENT (M5A)
MUSCULOSKELETAL (M5Z)
(N) NEUROLOGICAL PRODUCTS
ANAESTHETIC, INHALATION (N1A1)
ANAESTHETIC, INJECTABLE (N1A2)
ANAESTHETIC, LOCAL (N1B)
ANALGESIC, NSAID (N2B)
ANALGESIC, OTHER (N2Z)
ANTIEPILEPTIC (N3A)
ANTIPARKINSONIAN (N4A)
NEUROLEPTIC (N5A1)
HYPNOTIC/SEDATIVE (N5B)
ANXIOLYTIC (N5C)
ANTINEUROTIC (N5D)
PSYCHOSTIMULANT (N6B)
MEMORY ENHANCER (N6D)
MULTIPLE SCLEROSIS TREATMENT (N7A)
NEUROPROTECTIVE (N7C)
ANTIMIGRAINE (N8A)
DEPENDENCE TREATMENT (N9A)
ANTIDEPRESSANT (N10A)
NEUROLOGICAL (N11Z)
(P) ANTIPARASITIC PRODUCTS
AMOEBICIDE (P1A)
ANTHELMINTIC (P1B)
SCHISTOSOMICIDE (P1C)
ANTIMALARIAL (P1D)
SCABICIDE (P1E)
PROTOZOACIDE (P1G)
PARASITICIDE (P1Z)
(R) RESPIRATORY PRODUCTS
LUNG SURFACTANT (R3A)
EMPHYSEMA TREATMENT (R4A)
CYSTIC FIBROSIS TREATMENT (R4B)
EXPECTORANT/MUCOLYTIC (R5C)
ANTITUSSIVE (R5D)
ANTIASTHMA (R8A)
ANTIALLERGIC, NON-ASTHMA (R8B)
RESPIRATORY STIMULANT (R9A)
RESPIRATORY (R9Z)
(S) SENSORY PRODUCTS
ANTIGLAUCOMA (S1G)
OPHTHALMOLOGICAL (S1Z)
OTOLOGICAL (S2)
APPENDIX 1 PHARMACOLOGICAL CODES
APPENDIX 2 THERAPEUTIC ACTIVITIES
REFERENCES
TABLES
There are 633 tables tabulating information on prevalence/incidence drugs in use and in development, market values and forthcoming events for each Therapeutic category by drug type.
FIGURES
There are 196 figures illustrating trends data for 1995 � 2000 and activity status for each Therapeutic category by drug/agent type.
Methodology
Pharmaprojects forms the backbone of Scrip's Complete Guide to Therapeutic Trends. Data available in Pharmaprojects has been analysed to discern therapeutic trends and complemented with independent research from a wide range of sources including Scrip reports and Scrip newsletter.
Pharmaprojects is the scientific publication which monitors every significant new drug currently under development. At the present time details are contained for more than 25,000 developmental drugs and pharmaceutical formulations investigated since 1980. At any one time, just over 6,000 of these are undergoing active development. The remaining 19,000 or so are classified as either ceased or fully launched. The June 2000 issue of Pharmaprojects was used to compile this report. Incidence and market data was updated to the October 2000 issue.
© PJB Publications Ltd. 2001
All rights reserved.